Overbought Stocks — Valuation View · Pharmaceutical Preparations
30 stocks match the Overbought Stocks screen. Stocks with an RSI (14) above 70 — technically overbought, most-overbought first. Valuation columns. Filtered to Pharmaceutical Preparations. Data as of close · Checked
| PCRX | Pacira Biosciences, Inc. | $1.5B | 99.19 | 1.95 | 2.16 | 7.05 | — | 36.42 | +0.10% | 165K |
| VRDN | Viridian Therapeutics, Inc.De | $3.3B | -7.27 | 125.41 | 5.68 | 19.09 | — | 29.05 | +15.62% | 819K |
| RDY | Dr Reddys Laboratories Ltd | — | — | — | — | — | — | 14.77 | +3.18% | 248K |
| INM | InMed Pharmaceuticals Inc. | $10M | -0.75 | — | — | 9.04 | — | 1.80 | +6.82% | 1K |
| LYEL | Lyell Immunopharma, Inc. | $380M | -1.49 | 10564.96 | 1.97 | 4.13 | — | 15.47 | +42.98% | 53K |
| KRRO | Korro Bio, Inc. | $244M | -2.29 | 38.23 | 2.37 | 9.81 | — | 16.59 | +4.73% | 9K |
| XNCR | Xencor Inc | $2.6B | -22.30 | 13.11 | 4.69 | 44.09 | — | 35.03 | +14.33% | 113K |
| SLN | Silence Therapeutics Plc | $2.8B | -46.79 | 4561.03 | 72.91 | 38.93 | — | 19.79 | +0.00% | 70K |
| LKFT | Lakefront Biotherapeutics Nv | — | — | — | — | — | — | 34.10 | +6.07% | 27K |
| ZTS | Zoetis | $36.8B | 14.08 | 3.87 | 11.70 | 24.96 | 1.7% | 89.16 | +7.40% | 347K |
| SNY | Sanofi | — | — | — | — | — | — | 47.44 | +4.65% | 446K |
| GMAB | Genmab A/S | — | — | — | — | — | — | 55.08 | -0.74% | 328K |
| LLY | Lilly (Eli) | $1.33T | 48.37 | 15.43 | 33.13 | 273.09 | 0.5% | 1418.07 | +0.62% | 192K |
| GRFS | Grifols Sa | — | — | — | — | — | — | 8.60 | +0.53% | 52K |
| DMAC | DiaMedica Therapeutics Inc. | $582M | -15.50 | — | 15.18 | 113.44 | — | 10.79 | +7.68% | 30K |
| RPRX | Royalty Pharma Plc | $30.1B | 44.80 | 11.50 | 3.07 | 58.56 | 1.4% | 67.56 | +1.82% | 202K |
| ABT | Abbott Laboratories | $200.2B | 42.58 | 4.15 | 3.92 | 49.40 | 2.2% | 115.57 | +5.61% | 933K |
| PHAR | Pharming Group N.V. | — | — | — | — | — | — | 12.92 | +0.31% | 29 |
| BBIO | Bridgebio Pharma, Inc. | $15.2B | -20.72 | — | — | 9.91 | — | 77.97 | +5.36% | 383K |
| AZN | Astrazeneca Plc | — | — | — | — | — | — | 189.00 | +2.77% | 352K |
| TRAX | First Tracks Biotherapeutics, Inc. | $2.1B | — | — | 13.67 | 13.26 | — | 49.13 | +5.93% | 74K |
| SEPN | Septerna, Inc. | $2.2B | -92.21 | 22.60 | 5.78 | 26.40 | — | 47.88 | +9.47% | 57K |
| BHC | Bausch Health Companies Inc. | $3.1B | -3.71 | 0.28 | — | 1.26 | — | 8.34 | +2.58% | 253K |
| UTHR | United Therapeutics Corp | $25.9B | 21.02 | 8.12 | 4.12 | 21.76 | — | 607.43 | +0.95% | 68K |
| TAK | Takeda Pharmaceutical Co Ltd | — | — | — | — | — | — | 21.07 | +1.47% | 205K |
| ZYME | Zymeworks Inc. | $2.2B | -14.64 | 20.72 | 27.32 | 12.24 | — | 30.94 | +2.69% | 40K |
| ELAN | Elanco Animal Health Inc | $12.6B | -63.54 | 2.52 | 1.92 | 23.86 | — | 25.31 | +2.97% | 920K |
| NVS | Novartis Ag | — | — | — | — | — | — | 165.02 | +3.64% | 116K |
| ORKA | Oruka Therapeutics, Inc. | $6.7B | -50.56 | — | 6.03 | 25.03 | — | 101.48 | +1.85% | 40K |
| PVLA | Palvella Therapeutics, Inc. | $2.3B | -37.99 | — | 10.81 | 12.48 | — | 162.66 | +6.31% | 34K |
Source: SEC EDGAR/XBRL (fundamentals, shares) · Databento EQUS.MINI (EOD prices) · multiples, ratios & technicals computed by tradmap. Financials: Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it. A company reporting in another currency is shown in ≈ USD: its figures convert at the Federal Reserve H.10 rate of its price date (FRED), and without a rate its multiples are blank. This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis. Informational only — not financial advice.